$THLD concludes recruitment in pancreatic cancer drug Phase 2 trial

Threshold Pharma concludes recruitment in pancreatic cancer drug Phase 2 trial - Pharmaceutical Business Review:

"Threshold Pharmaceuticals has concluded patient recruitment in a multi-center, randomized, controlled, crossover Phase 2 clinical trial of TH-302 in patients with pancreatic cancer.
TH-302 is a novel small molecule tumor selective hypoxia-activated prodrug (HAP) that specifically targets tumor hypoxia and is applicable to a broad range of solid tumors.
Earlier, the company targeted to recruit around 165 patients, but the company has now recruited approximately 200 patients in the trial, which has automatically increased the statistical power of the study to greater than 80%.
The primary endpoint of the trial is progression-free survival.
However, the secondary endpoints are overall response rate, overall survival, event-free survival, CA 19-9 response rate as well as various safety parameters"